70 results on '"Vessella, Robert L."'
Search Results
2. LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics
3. Amplification of the 9p13.3 chromosomal region in prostate cancer
4. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer
5. Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma‐Like by Reprogramming
6. Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer
7. Epigenetically altered miR‐193b targets cyclin D1 in prostate cancer
8. Efficacy studies of an antibody‐drug conjugate PSMA‐ADC in patient‐derived prostate cancer xenografts
9. Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases
10. Establishment and serial passage of cell cultures derived from LuCaP xenografts
11. Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases
12. Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: Results from the University of Washington Rapid Autopsy Series
13. Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance
14. Serum prosaposin levels are increased in patients with advanced prostate cancer
15. The miR‐15a‐miR‐16‐1 locus is homozygously deleted in a subset of prostate cancers
16. Expression of cancer/testis antigens in prostate cancer is associated with disease progression
17. Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability
18. Genetic alterations and changes in expression of histone demethylases in prostate cancer
19. Low dose, alternating electric current inhibits growth of prostate cancer
20. The expression of osteoclastogenesis‐associated factors and osteoblast response to osteolytic prostate cancer cells
21. Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells
22. Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis
23. Comprehensive mutational analysis and mRNA isoform quantification ofTP63in normal and neoplastic human prostate cells
24. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid
25. The current state of preclinical prostate cancer animal models
26. Overexpression of protease‐activated receptors‐1,‐2, and‐4 (PAR‐1, ‐2, and ‐4) in prostate cancer
27. The role of tumor microenvironment in prostate cancer bone metastasis
28. Genetic aberrations in prostate cancer by microarray analysis
29. Telomerase activity in disseminated prostate cancer cells
30. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late‐stage prostate cancer
31. Screening of genetic and expression alterations of SRC1 gene in prostate cancer
32. Mutation screening of the androgen receptor promoter and untranslated regions in prostate cancer
33. Microsatellite instability and mismatch repair target gene mutations in cell lines and xenografts of prostate cancer
34. Amplification and overexpression of prosaposin in prostate cancer
35. Hyperbaric oxygen does not accelerate latent in vivo prostate cancer: implications for the treatment of radiation-induced haemorrhagic cystitis
36. Lineage relationship between LNCaP and LNCaP‐derived prostate cancer cell lines
37. Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer
38. Characterization of C4–2 Prostate Cancer Bone Metastases and Their Response to Castration
39. RAD21 and KIAA0196 at 8q24 are amplified and overexpressed in prostate cancer
40. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients
41. Human pHyde is not a classical tumor suppressor gene in prostate cancer
42. Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia
43. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function
44. A novel method of generating prostate cancer metastases from orthotopic implants
45. Insulin‐like growth factor binding protein‐related protein 1 (IGFBP‐rP1/mac 25) is reduced in human prostate cancer and is inversely related to tumor volume and proliferation index in Lucap 23.12 xenografts
46. LuCaP 35: A new model of prostate cancer progression to androgen independence
47. Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors
48. KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer
49. Molecular characterization of prostatic small-cell neuroendocrine carcinoma
50. Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.